

# **Market Announcement**

13 June 2024

## Telix Pharmaceuticals Limited (ASX: TLX) - Trading Halt

#### **Description**

The securities of Telix Pharmaceuticals Limited ('TLX') will be placed in trading halt at the request of TLX, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 17 June 2024 or when the announcement is released to the market.

### Issued by

**ASX Compliance** 



**Telix Pharmaceuticals Limited** 

ACN 616 620 369 55 Flemington Road North Melbourne, Victoria, 3051, Australia **telixpharma.com** 

Jonathan Bisset Senior Adviser, Listings Compliance Level 50, South Tower, Rialto 525 Collins Street Melbourne VIC 3000 13 June 2024 By email only

jonathan.bisset@asx.com.au tradinghaltsmelbourne@asx.com.au

Dear Jonathan

#### Request for trading halt

Telix Pharmaceuticals Limited (ASX:TLX, Telix, the Company) requests that its securities be placed in a trading halt from the commencement of trading today pursuant to ASX Listing Rule 17.1.

The trading halt is requested pending an announcement in relation to the completion of the pricing and allocation processes for Telix's proposed United States (US) initial public offering of new American Depositary Shares (ADSs) representing ordinary shares and concurrent listing of the ADSs on the Nasdaq Global Market (US Offering). Telix expects to make an announcement in relation to the pricing of the US Offering on 14 June 2024 and for the trading halt to continue after that announcement. Telix expects to make a subsequent announcement in relation to the completion of the allocation process for the US Offering on 17 June 2024 (Completion Announcement).

Telix requests that the trading halt remains in place until the earlier of:

- (a) Telix making the Completion Announcement; or
- (b) the commencement of trading on 17 June 2024.

Telix is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

If you have any further questions, please do not hesitate to contact me.

Yours sincerely

Genevieve Ryan Company Secretary

**Telix Pharmaceuticals Limited**